References
[1] SARESELLA M, RAINONE V, AL-DAGHRI N M, et al.The PD-1/PD-L1 pathway in human pathology[J].Current molecular medicine, 2012, 12(3):259-267.
[2] OLIVE D.PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1[J].International immunology, 2010, 22(8):651-660.
[3] LESTERHUIS W J, STEER H, LAKE R A.PD-L2 is predominantly expressed by Th2 cells[J].Molecular immunology, 2011,49(1-2):1-3.
[4] JIN H T, AHMED R, OKAZAKI T.Role of PD-1 in regulating T-cell immunity[J].Current Topics in Microbiology and immunology, 2011,350:17-37.
[5] BUTTE M J, KEIR M E, PHAMDUY T B, et al.Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J].Immunity,2007,27(1):111-122.
[6] SALAMA A D, CHITNIS T, IMITOLA J, et al.Critical role of the programmed death-1(PD-1) pathway in regulation of experimental autoimmune encephalomyelitis[J].The journal of experimental medicine, 2003,198(1):71-78.
[7] YOSHIDA T, JIANG F, HONJO T, et al.PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice[C]//Proceedings of the National Academy of Sciences of the United States of America,2008,105(9):3533-3538.
[8] FIFE B T, PAUKEN K E, EAGAR T N, et al.Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal[J].Nature immunology,2009,10(11):1185-1192.
[9] GONG J, CHEHRAZI-RAFFLE A, REDDI S, et al.Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations[J].Journal for immunother therapy of cancer, 2018, 6(1):8.
[10] ROWSHANRAVAN B, HALLIDAY N, SANSOM D M.CTLA-4: a moving target in immunotherapy[J].Blood, 2018,131(1):58-67.
[11] SU K Y, WATANABE A, YEH C H, et al.Efficient culture of human naive and memory B cells for use as apcs[J].Journal of immunology, 2016,197(10):4163-4176.
[12] QURESHI O S, KAUR S, HOU T Z, et al.Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation[J].Journal of biological chemistry, 2012,287(12):9429-9440.
[13] WALKER L S, SANSOM D M.Confusing signals: recent progress in CTLA-4 biology[J].Trends in immunology, 2015,36(2):63-70.
[14] KONG K F, FU G, ZHANG Y, et al.Protein kinase C-η controls CTLA-4-mediated regulatory T cell function[J].Nature immunology, 2014,15(5):465-472.
[15] RUDD C E.The reverse stop-signal model for CTLA4 function[J].Nature reviews immunology, 2008,8(2):153-160.
[16] MALHOTRA D, LINEHAN J L, DILEEPAN T, et al.Tolerance is established in polyclonal CD4(+) T cells by distinct mechanisms, according to self-peptide expression patterns[J].Nature immunology, 2016,17(2):187-195.
[17] MARCHINGO J M, KAN A, SUTHERLAND R M, et al.T cell signaling.Antigen affinity,costimulation, and cytokine inputs sum linearly to amplify T cell expansion[J].Science,2014,346(6213):1123-1127.
[18] ISE W, KOHYAMA M, NUTSCH K M, et al.CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms[J].Nature immunology, 2010,11(2):129-135.
[19] KLOCKE K, SAKAGUCHI S, HOLMDAHL R, et al.Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood[C]//Proceedings of the National Academy of Sciences, 2016,113(17): E2383-E2392.
[20] SCHUBERT D, BODE C, KENEFECK R, et al.Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations[J].Nature medicine, 2014,20(12):1410-1416.
[21] SHARMA P, ALLISON J P.The future of immune checkpoint therapy[J].Science,2015,348(6230):56-61.
[22] BOUTROS C, TARHINI A, ROUTIER E, et al.Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J].Nature reviews clinical oncology,2016,13(8):473-486.
[23] OH D Y, CHAM J, ZHANG L, et al.Immune toxicities elicited by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire[J].Cancer research, 2017, 77(6):1322-1330.
[24] MAEDA Y, NISHIKAWA H, SUGIYAMA D, et al.Detection of self-reactive CD8(+) T cells with an anergic phenotype in healthy individuals[J].Science, 2014, 346(6216):1536-1540.(https://www.daowen.com)
[25] SANGMOON L, JIN S M, CHO-RONG L, et al.Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4[J].Journal of allergy & clinical immunology, 2016, 137(1):327-330.
[26] KÖHLER G, MILSTEIN C.Continuous cultures of fused cells secreting antibody of predefined specificity[J].Nature.1975, 256(5517):495-497.
[27] MARTINEZ FORERO I, OKADA H, TOPALIAN S L, et al.Workshop on immunotherapy combinations[C]//Society for Immunotherapy of Cancer annual meeting Bethesda,November 3, 2011.Journal of translational medicine, 2012, 10:108.
[28] WOOTLA B, WATZLAWIK J O, STAVROPOULOS N, et al.Recent advances in monoclonal antibody therapies for multiple sclerosis[J].Expert opinion on biological therapy,2016, 16(6):827-839.
[29] WOLCHOK J D, CHIARION-SILENI V, GONZALEZ R, et al.Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J].The New England journal of medicine, 2017, 377(14):1345-1356.
[30] POSTOW M A, SIDLOW R, HELLMANN M D.Immune-related adverse events associated with immune checkpoint blockade[J].New England journal of medicine, 2018, 378(2):158-168.
[31] Hofmann L, Forschner A, Loquai C, et al.Cutaneous, gastrointestinal, hepatic, endocrine,and renal side-effects of anti-PD-1 therapy[J].European journal of cancer, 2016, 60:190-209.
[32] KATO K, NARITA Y, MITANI S, et al.Efficacy of cytotoxic agents after progression on Anti-PD-(L)1 antibody for pre-treated metastatic gastric cancer[J].Anticancer research, 2020,40(4):2247-2255.
[33] TARHINI A A, LEE S J, HODI F S, et al.Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon Alfa-2b for resected high-risk melanoma: North American Intergroup E1609[J].Journal of clinical oncology, 2020, 38(6):567-575.
[34] Brahmer J R, Lacchetti C, Schneider B J, et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J].Journal of clinical oncology, 2018,36(17):1714-1768.
[35] BARROSO-SOUSA R, BARRY W T, GARRIDO-CASTRO A C, et al.Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens:a systematic review and meta-analysis[J].JAMA oncology, 2018, 4(2):173-182.
[36] FIRWANA B, RAVILLA R, RAVAL M, et al.Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors[J].Journal of oncology pharmacy practice, 2017,23(8):620-624.
[37] JESPERSEN H, BJURSTEN S, NY L, et al.Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases[J].The lancet oncology, 2018, 19(6): e327.
[38] KISHI S, MINATO M, SAIJO A, et al.IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma[J].Internal medicine, 2018,57(9):1259-1263.
[39] TAJMIR-RIAHI A, BERGMANN T, SCHMID M, et al.Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy[J].Journal of immunotherapy, 2018, 41(1):35-38.
[40] MOSLEHI J J, SALEM J E, SOSMAN J A, et al.Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J].Lancet, 2018, 391(10124).
[41] LIDAR M, GIAT E, GARELICK D, et al.Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors[J].Autoimmunity reviews, 2018, 17(3):284-289.
[42] GOLDINGER S M, STIEGER P, MEIER B, et al.Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy[J].Clinical cancer research, 2016, 22(16):4023-4029.
[43] CAPPELLI L C, GUTIERREZ A K, BAER A N, et al.Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab[J].Annals of the rheumatic diseases, 2017,76(1):43-50.
[44] RITTMEYER A, BARLESI F, WATERKAMP D, et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label,multicentre randomised controlled trial[J].Lancet, 2017, 389(10066):255-265.
[45] BARLESI F, VANSTEENKISTE J, SPIGEL D, et al.Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study[J].The lancet oncology, 2018,19(11):1468-1479.
[46] HEINZERLING L, DE TONI E, SCHETT G, et al.Checkpoint inhibitors[J].Dtsch Arztebl int ernational, 2019, 116(8):119-126.
[47] HASSEL J C, HEINZERLING L, ABERLE J, et al.Combined immune checkpoint blockade(anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions[J].Cancer treatment reviews, 2017, 57:36-49.
[48] O'KANE G M, LYONS T G, COLLERAN G C, et al.Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma[J].Oncology research and treatment, 2014, 37(12):757-760.